Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller? | Zendy

Cemil Bilir | Zendy; Can Sarısözen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?

Author(s) -

Cemil Bilir,

Can Sarısözen

Publication year - 2017

Publication title -

journal of oncological sciences

Language(s) - English

Resource type - Journals

ISSN - 2452-3364

DOI - 10.1016/j.jons.2017.04.001

Subject(s) - indoleamine 2,3 dioxygenase , kynurenine , kynurenine pathway , enzyme , dioxygenase , chemistry , tryptophan , limiting , cancer immunotherapy , immunotherapy , intracellular , cancer research , immune system , biochemistry , biology , amino acid , immunology , mechanical engineering , engineering

Tryptophan (Trp) is one of the important essential amino acids and Kynurenine pathway (KP) is the first and rate limiting step of degrading Trp to active metabolites. Recent studies showed that KP metabolites have antimicrobial and immunosuppressive roles. The main controller enzyme of this pathway is indoleamine-2,3-dioxygenase (IDO). IDO is an intracellular monomeric, heme-containing enzyme that controls the Trp breakdown in the KP. In this review, we discuss IDO functions on cancer progression and prognosis, and possible therapeutic aspects of inhibition of IDO on cancer immunotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research